3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
3
Phase EARLY_PHASE1
2
Phase NA
1
Status
Not yet recruiting
2
Completed
1
Sponsor Class
OTHER
72
INDUSTRY
23
NIH
9
OTHER_GOV
3
NETWORK
1
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
3
Conditions
Uveal Melanoma
3
Melanoma
3
Interventions
fludarabine
7
Cyclophosphamide
7
Nivolumab
6
Metformin
4
pembrolizumab
3
fludarabine phosphate
3
Radiotherapy
3
Melphalan
3
Ipilimumab
3
Interleukin-2
3
Injections
3
S 1 (combination)
2
Irinotecan
2
tremelimumab
1
selinexor
1
parsaclisib
1
olaparib
1
nabiximols
1
ivarmacitinib
1
durvalumab
1
defactinib
1
decitabine and cedazuridine drug combination
1
cedazuridine
1
carfilzomib
1
apatorsen
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Topotecan
1
Rituximab
1
Radiosurgery
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1
×
OTHER_GOV
×
Interleukin-2
×
Clear all
NCT04812470
2025-09-22
HAITILS
Vastra Gotaland Region
Phase 1
Completed
8 enrolled
NCT07183852
2025-09-19
GoTIL-01
Vastra Gotaland Region
Phase 1
Not yet recruiting
18 enrolled
NCT05903937
2023-06-15
HAITILS-PHP
Vastra Gotaland Region
Phase 1
Not yet recruiting
6 enrolled